Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Barbie

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Cancers|August 26, 2023
Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor CellsThomas J Gerton, Allen Green, Marco Campisi, et al.
Cancer Research|December 21, 2017
ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase InhibitorsHideki Terai, Shunsuke Kitajima, Danielle S Potter, et al.
Research Square|February 26, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesVaradha Balaji Venkadakrishnan, Adam G Presser, Richa Singh, et al.
The Journal of Clinical Investigation|November 4, 2014
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growthThanh U Barbie, Gabriela Alexe, Amir R Aref, et al.
Lab on a Chip|September 6, 2018
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockadeAmir R Aref, Marco Campisi, Elena Ivanova, et al.
JAMA Oncology|October 24, 2024
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical TrialKartik Sehgal, Theodora Pappa, Kee-Young Shin, et al.
Nature Communications|August 8, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesVaradha Balaji Venkadakrishnan, Adam G Presser, Richa Singh, et al.
Cancer Discovery|June 15, 2013
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer driversDaniel Hagerstrand, Alexander Tong, Steven E Schumacher, et al.
Cell Reports. Medicine|June 21, 2025
Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platformYuqing Zhang, Zehua Li, Jessica Ritter, et al.
Cancer Research|September 6, 2022
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung CancerRyohei Yoshida, Maria Saigi, Tetsuo Tani, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Cancers|August 26, 2023
Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor CellsThomas J Gerton, Allen Green, Marco Campisi, et al.
Cancer Research|December 21, 2017
ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase InhibitorsHideki Terai, Shunsuke Kitajima, Danielle S Potter, et al.
Research Square|February 26, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesVaradha Balaji Venkadakrishnan, Adam G Presser, Richa Singh, et al.
The Journal of Clinical Investigation|November 4, 2014
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growthThanh U Barbie, Gabriela Alexe, Amir R Aref, et al.
Lab on a Chip|September 6, 2018
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockadeAmir R Aref, Marco Campisi, Elena Ivanova, et al.
JAMA Oncology|October 24, 2024
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical TrialKartik Sehgal, Theodora Pappa, Kee-Young Shin, et al.
Nature Communications|August 8, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesVaradha Balaji Venkadakrishnan, Adam G Presser, Richa Singh, et al.
Cancer Discovery|June 15, 2013
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer driversDaniel Hagerstrand, Alexander Tong, Steven E Schumacher, et al.
Cell Reports. Medicine|June 21, 2025
Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platformYuqing Zhang, Zehua Li, Jessica Ritter, et al.
Cancer Research|September 6, 2022
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung CancerRyohei Yoshida, Maria Saigi, Tetsuo Tani, et al.
Pageof 12